EyeBiotech Ltd.

7 clinical trials · Sponsor

Record	Firm	Date
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (NCT07496567)	EyeBiotech Ltd.	2026-04-15
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (NCT07440225)	EyeBiotech Ltd.	2026-03-27
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO (NCT07205887)	EyeBiotech Ltd.	2025-09-12
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (NCT06957080)	EyeBiotech Ltd.	2025-04-16
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (NCT06664502)	EyeBiotech Ltd.	2024-11-12
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (NCT06571045)	EyeBiotech Ltd.	2024-08-07
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (NCT05919693)	EyeBiotech Ltd.	2023-06-12

Every clearance here is in the API, with alerts when new ones post.